Literature DB >> 22696658

Lethal monkeypox virus infection of CAST/EiJ mice is associated with a deficient gamma interferon response.

Patricia L Earl1, Jeffrey L Americo, Bernard Moss.   

Abstract

Monkeypox virus (MPXV) is endemic in Africa, where it causes disease in humans resembling smallpox. A recent importation of MPXV-infected animals into the United States raises the possibility of global spread. Rodents comprise the major reservoir of MPXV, and a variety of such animals, even those native to North America, are susceptible. In contrast, common inbred strains of mice, including BALB/c and C57BL/6, are greatly resistant to MPXV. However, several inbred strains of mice derived from wild mice, including CAST/EiJ, exhibit morbidity and mortality at relatively low inoculums of MPXV. Elucidating the basis for the susceptibility of CAST/EiJ mice could contribute to an understanding of MPXV pathogenicity and host defense mechanisms and enhance the value of this mouse strain as a model system for evaluation of therapeutics and vaccines. Here we compared virus dissemination and induced cytokine production in CAST/EiJ mice to those in the resistant BALB/c strain. Following intranasal infection, robust virus replication occurred in the lungs of both strains, although a relatively higher inoculum was required for BALB/c. However, while spread to other internal organs was rapid and efficient in CAST/EiJ mice, the virus was largely restricted to the lungs in BALB/c mice. Gamma interferon (IFN-γ) and CCL5 were induced in lungs of BALB/c mice concomitant with virus replication but not in CAST/EiJ mice. The importance of IFN-γ in protection against MPXV disease was demonstrated by the intranasal administration of the mouse cytokine to CAST/EiJ mice and the resulting protection against MPXV. Furthermore, C57BL/6 mice with inactivation of the IFN-γ gene or the IFN-γ receptor gene exhibited enhanced sensitivity to MPXV.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22696658      PMCID: PMC3416162          DOI: 10.1128/JVI.00162-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  A silent enzootic of an orthopoxvirus in Ghana, West Africa: evidence for multi-species involvement in the absence of widespread human disease.

Authors:  Mary G Reynolds; Darin S Carroll; Victoria A Olson; Christine Hughes; Jack Galley; Anna Likos; Joel M Montgomery; Richard Suu-Ire; Mubarak O Kwasi; J Jeffrey Root; Zach Braden; Jason Abel; Cody Clemmons; Russell Regnery; Kevin Karem; Inger K Damon
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

2.  The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis).

Authors:  G M Zaucha; P B Jahrling; T W Geisbert; J R Swearengen; L Hensley
Journal:  Lab Invest       Date:  2001-12       Impact factor: 5.662

3.  A study of the vaccinia virus interferon-gamma receptor and its contribution to virus virulence.

Authors:  Julian A Symons; David C Tscharke; Nicola Price; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2002-08       Impact factor: 3.891

4.  The detection of monkeypox in humans in the Western Hemisphere.

Authors:  Kurt D Reed; John W Melski; Mary Beth Graham; Russell L Regnery; Mark J Sotir; Mark V Wegner; James J Kazmierczak; Erik J Stratman; Yu Li; Janet A Fairley; Geoffrey R Swain; Victoria A Olson; Elizabeth K Sargent; Sue C Kehl; Michael A Frace; Richard Kline; Seth L Foldy; Jeffrey P Davis; Inger K Damon
Journal:  N Engl J Med       Date:  2004-01-22       Impact factor: 91.245

5.  Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox.

Authors:  Geeta Chaudhri; Vijay Panchanathan; R Mark L Buller; Alfons J M van den Eertwegh; Eric Claassen; Jie Zhou; Rosalind de Chazal; Jon D Laman; Gunasegaran Karupiah
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-07       Impact factor: 11.205

6.  Susceptibility of some rodent species to monkeypox virus, and course of the infection.

Authors:  S S Marennikova; E M Seluhina
Journal:  Bull World Health Organ       Date:  1976       Impact factor: 9.408

7.  Prevention of lethal respiratory vaccinia infections in mice with interferon-alpha and interferon-gamma.

Authors:  Ge Liu; Qingzhu Zhai; Dustin J Schaffner; Aiguo Wu; Adiamseged Yohannes; Tanisha M Robinson; Matt Maland; Jay Wells; Thomas G Voss; Charlie Bailey; Ken Alibek
Journal:  FEMS Immunol Med Microbiol       Date:  2004-04-09

8.  Experimental infection of ground squirrels (Spermophilus tridecemlineatus) with monkeypox virus.

Authors:  Robert B Tesh; Douglas M Watts; Ellena Sbrana; Marina Siirin; Vsevolod L Popov; Shu-Yuan Xiao
Journal:  Emerg Infect Dis       Date:  2004-09       Impact factor: 6.883

9.  A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus.

Authors:  Jennifer Stabenow; R Mark Buller; Jill Schriewer; Cheri West; John E Sagartz; Scott Parker
Journal:  J Virol       Date:  2010-02-03       Impact factor: 6.549

10.  Monkeypox transmission and pathogenesis in prairie dogs.

Authors:  Jeannette Guarner; Bill J Johnson; Christopher D Paddock; Wun-Ju Shieh; Cynthia S Goldsmith; Mary G Reynolds; Inger K Damon; Russell L Regnery; Sherif R Zaki
Journal:  Emerg Infect Dis       Date:  2004-03       Impact factor: 6.883

View more
  32 in total

Review 1.  The effects of post-exposure smallpox vaccination on clinical disease presentation: addressing the data gaps between historical epidemiology and modern surrogate model data.

Authors:  M Shannon Keckler; Mary G Reynolds; Inger K Damon; Kevin L Karem
Journal:  Vaccine       Date:  2013-08-27       Impact factor: 3.641

2.  Exposure of rhesus monkeys to cowpox virus Brighton Red by large-particle aerosol droplets results in an upper respiratory tract disease.

Authors:  Reed F Johnson; Dima A Hammoud; Donna L Perry; Jeffrey Solomon; Ian N Moore; Matthew G Lackemeyer; Jordan K Bohannon; Philip J Sayre; Mahnaz Minai; Amy B Papaneri; Katie R Hagen; Krisztina B Janosko; Catherine Jett; Kurt Cooper; Joseph E Blaney; Peter B Jahrling
Journal:  J Gen Virol       Date:  2016-05-09       Impact factor: 3.891

3.  A review of experimental and natural infections of animals with monkeypox virus between 1958 and 2012.

Authors:  Scott Parker; R Mark Buller
Journal:  Future Virol       Date:  2013-02-01       Impact factor: 1.831

4.  Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.

Authors:  Donald F Smee
Journal:  Future Virol       Date:  2013-09       Impact factor: 1.831

5.  Insufficient Innate Immunity Contributes to the Susceptibility of the Castaneous Mouse to Orthopoxvirus Infection.

Authors:  Patricia L Earl; Jeffrey L Americo; Bernard Moss
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

6.  Comparative live bioluminescence imaging of monkeypox virus dissemination in a wild-derived inbred mouse (Mus musculus castaneus) and outbred African dormouse (Graphiurus kelleni).

Authors:  Patricia L Earl; Jeffrey L Americo; Catherine A Cotter; Bernard Moss
Journal:  Virology       Date:  2014-12-02       Impact factor: 3.616

7.  Evasion of the Innate Immune Type I Interferon System by Monkeypox Virus.

Authors:  William D Arndt; Samantha Cotsmire; Kelly Trainor; Heather Harrington; Kevin Hauns; Karen V Kibler; Trung P Huynh; Bertram L Jacobs
Journal:  J Virol       Date:  2015-08-05       Impact factor: 5.103

Review 8.  Drug Development against Smallpox: Present and Future.

Authors:  Déborah Delaune; Frédéric Iseni
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.938

Review 9.  Wild-derived mice: from genetic diversity to variation in immune responses.

Authors:  Alexander Poltorak; Svetlana Apalko; Sergei Sherbak
Journal:  Mamm Genome       Date:  2018-07-28       Impact factor: 3.224

10.  Transcriptional analysis of the three Nlrp1 paralogs in mice.

Authors:  Inka Sastalla; Devorah Crown; Seth L Masters; Andrew McKenzie; Stephen H Leppla; Mahtab Moayeri
Journal:  BMC Genomics       Date:  2013-03-18       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.